A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Inclusion Criteria:

1. Subjects voluntarily join the study and sign an informed consent form, have goodcompliance and cooperate with follow-up;
2. Male or female patients between the ages of 18-75;
3. Patients diagnosed as gastric adenocarcinoma by histology or cytology;
4. Stage: Locally advanced stage (T3-4aN1-3M0);
5. Have not received other immunotherapy drugs or chemotherapy drugs in the past;
6. ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points;
7. Has sufficient organ and bone marrow function

Exclusion Criteria:

1. Other malignant tumors that have appeared or are currently suffering from within 5years, except for cured cervical carcinoma in situ, non-melanoma skin cancer andsuperficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1 (tumor infiltration basement membrane)];
2. A distant metastasis occurs;
3. Those who have multiple factors that affect oral medications (such as inability toswallow, chronic diarrhea, etc.);
4. Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AEV5.0 grade ≥ 2 dyspnea);
5. Patients with any severe and/or uncontrollable disease；
6. Patients with gastrointestinal diseases with bleeding tendency (such as activegastrointestinal ulcers) or patients determined by the researcher to causegastrointestinal bleeding, perforation or obstruction
7. Patients whose imaging shows that the tumor has invaded the tissues around importantblood vessels or the investigator judges that the tumor is likely to invade importantblood vessels and cause fatal bleeding during the follow-up study;
8. Received glucocorticosteroid or immunosuppressive therapy within 7 days beforegrouping;
9. Regardless of the severity, patients with any signs of bleeding or medical history;within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTCAE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture
10. Those who have had arterial/venous thrombotic events within 6 months, such ascerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosisand pulmonary embolism;
11. People with a history of psychotropic drug abuse and unable to quit or have mentaldisorders;
12. Participated in other anti-tumor drug clinical trials within four weeks;
13. According to the judgment of the investigator, those with concomitant diseases thatseriously endanger the safety of the patient or affect the completion of the study;
14. Female patients who are pregnant or breastfeeding;
15. Known hypersensitivity to any study drug.